The American Journal of Managed Care14d
Final MIRASOL Trial Analysis Confirms Consistent Efficacy of Mirvetuximab Soravtansine
The final analysis showed similar overall survival, progression-free survival, and objective response rates, with no new safety signals identified compared with the primary analysis. The primary ...
TipRanks on MSN15d
AbbVie announces final analysis of Phase 3 MIRASOL trial
AbbVie (ABBV) announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ...
Cure Today15d
Elahere Shows Consistent Survival Benefit in Ovarian Cancer Subset
Elahere showed superior efficacy over chemotherapy in progression-free survival, objective response rate, and overall survival in the MIRASOL trial. The treatment reduced the risk of tumor progression ...
The American Journal of Managed Care7d
Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer
Mirvetuximab soravtansine shows no significant HRQoL detriments despite TEOEs in FRα+ platinum-resistant ovarian cancer patients. The phase 3 MIRASOL trial confirms improved progression-free and ...
Yahoo Finance15d
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer
US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its antibody-drug conjugate (ADC) Elahere against chemotherapy for treating ...
Yahoo Finance17d
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...